Showing 581 - 600 results of 101,477 for search '(( 5 non decrease ) OR ( 5 ((step decrease) OR (((we decrease) OR (a decrease)))) ))', query time: 1.63s Refine Results
  1. 581

    Average radiant efficiency (± SEM) in equally sized regions of interest (ROIs) of the non-pregnant uterus. by Kalman F. Szucs (19353218)

    Published 2024
    “…<p>A significant decrease in αvβ3 integrin was observed in the PET imaging procedure. (***: p < 0.001).…”
  2. 582
  3. 583
  4. 584
  5. 585

    Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>. by Giorgia Urbinati (554921)

    Published 2015
    “…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
  6. 586

    Nur77 knockdown decreases cell viability and proliferation. by Alexa Tenga (2161780)

    Published 2016
    “…<p>(A) Daoy cells were transfected with 20 nM siNur77 or non-targeting control (NT), and cell viability was measured via the CellTiter-Glo assay every day for 3 days. …”
  7. 587
  8. 588

    Human preterm infants diagnosed with IUGR have decreased Paneth cell counts compared to preterm non-IUGR control infants. by Camille M. Fung (844334)

    Published 2016
    “…(A) IUGR infants had similar numbers of goblet cells per 100 epithelial cells compared to non-IUGR infants (p = 0.5). …”
  9. 589

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  10. 590
  11. 591

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  12. 592
  13. 593
  14. 594

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”
  15. 595
  16. 596

    Intracameral injections of ATX inhibitor decreases IOP in rabbits. by Padma Iyer (141117)

    Published 2012
    “…Drug treated eyes showed a significant decrease in IOP from the baseline (by 6–7 mm Hg) at 24 and 48 hrs based on paired t-test. …”
  17. 597
  18. 598
  19. 599

    Decreased cell stiffness after dissociation of intercellular adhesion. by Kristina Seiffert-Sinha (627059)

    Published 2014
    “…Cell stiffness was measured before and after the nanorobotic surgery and decreases from 30.0±1.5 kPa to 20.5±2.8 kPa, respectively. …”
  20. 600

    Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis by Raj Vuppalanchi (458660)

    Published 2013
    “…In this study, we examined if certain microRNAs (miRNA) are associated with decreased hepatic CYP3A activity in cirrhosis.…”